Brian Weinstein
Stock Analyst at William Blair
(0.65)
# 4,062
Out of 5,169 analysts
12
Total ratings
42.86%
Success rate
-13.1%
Average return
Main Sectors:
Stocks Rated by Brian Weinstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDSX Biodesix | Upgrades: Outperform | n/a | $16.09 | - | 3 | Feb 27, 2026 | |
| BDX Becton, Dickinson and Company | Downgrades: Market Perform | n/a | $158.08 | - | 1 | May 1, 2025 | |
| TXG 10x Genomics | Downgrades: Market Perform | n/a | $17.35 | - | 2 | Jul 15, 2022 | |
| GKOS Glaukos | Upgrades: Outperform | n/a | $103.22 | - | 3 | Feb 3, 2022 | |
| SERA Sera Prognostics | Initiates: Outperform | n/a | $1.91 | - | 1 | Aug 9, 2021 | |
| QDEL QuidelOrtho | Upgrades: Outperform | n/a | $17.03 | - | 2 | Jul 18, 2017 |
Biodesix
Feb 27, 2026
Upgrades: Outperform
Price Target: n/a
Current: $16.09
Upside: -
Becton, Dickinson and Company
May 1, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $158.08
Upside: -
10x Genomics
Jul 15, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $17.35
Upside: -
Glaukos
Feb 3, 2022
Upgrades: Outperform
Price Target: n/a
Current: $103.22
Upside: -
Sera Prognostics
Aug 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.91
Upside: -
QuidelOrtho
Jul 18, 2017
Upgrades: Outperform
Price Target: n/a
Current: $17.03
Upside: -